急性不补偿性心力衰竭中的 ангиотензин-neprilysin 抑制:随机对照试验的元分析
Hosam I Taha1, Abdalhakim Shubietah2, Bashar M Al Zoubi3
1Faculty of Medicine, Tanta University, Tanta, Egypt.
Future cardiology
|July 21, 2025
概括
ангиотензин受体-neprilysin抑制剂 (ARNI) 降低心力衰竭住院和死亡率后急性去补偿. 虽然ARNI对心血管和结局有效,但与ACE抑制剂或ARB相比,ARNI的使用增加了症状性低血压的风险.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- ангиотензин受体-neprilysin抑制剂 (ARNI) 是已建立的治疗慢性心力衰竭 (HF) 减少喷射分数.
- 在急性不补偿性心力衰竭 (ADHF) 稳定后ARNI的疗效和安全性仍然不完全理解.
- 这一元分析研究了ARNI与血管激素转化酶抑制剂 (ACEI) 或血管激素受体抑制剂 (ARB) 相比,在ADHF后的环境中.
研究的目的:
- 在ADHF稳定后的患者中,评估ARNI与ACEI/ARB相比的有效性.
- 评估ARNI对ADHF后心血管和结局的影响.
- 确定ARNI的安全性概况,特别是症状性低血压等不良事件的风险.
主要方法:
- 进行了随机对照试验 (RCT) 的元分析.
- 文献搜索包括到2024年11月的PubMed,Scopus,Web of Science,Embase和CENTRAL数据库.
- 数据综合利用风险比率 (RR) 和标准化平均差异 (SMD) 以95%的置信区间 (CI).
主要成果:
- 使用ARNI显著降低了心力衰竭再住院/所有原因死亡率 (RR:0.71) 和心力衰竭再住院 (RR:0.73).
- 在稳定后4周和8周,ARNI还改善了功能 (RR:0.80) 并降低了NT-proBNP水平.
- 然而,ARNI使用与症状性低血压的风险增加有关 (RR: 1.33).
结论:
- 在ADHF稳定后启动ARNI与ACEI/ARB相比,提供了优越的心血管和益.
- 增强的ARNI疗效伴随着更高的症状性低血压的发生率.
- 在临床决策过程中,在处方ARNI后ADHF时,应权衡益处与低血压风险的增加.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
511
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
511
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
891
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
891
01:30Heart Failure V: Medical Management
26
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
26
01:25Antihypertensive Drugs: Direct Renin Inhibitors
830
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
830
01:29Heart Failure II: Pathophysiology
45
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
45
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
928
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
928